Details for Patent: 9,770,427

Title:	Antiviral treatments
Abstract:	The invention provides unit dosage forms, kits, and methods and useful for treating viral infections.
Inventor(s):	Babu; Yarlagadda S (Birmingham, AL), Chand; Pooran (Birmingham, AL), Bantia; Shanta (Birmingham, AL), Arnold; Shane (Hoover, AL), Kilpatrick; John Michael (Helena, AL)
Assignee:	BioCryst Pharmaceuticals, Inc. (Durham, NC)
Filing Date:	Jun 24, 2014
Application Number:	14/313,738
Claims:	1. A method for treating a viral infection in a human comprising administering in a single intravenous administration per day over a course of treatment an effective anti-viral amount of a compound of formula I: ##STR00026## or a pharmaceutically acceptable salt thereof, to the human, wherein the viral infection is a type A, type B, H3N2, H1N1, H5N1, avian, or seasonal influenza infection. 2. The method of claim 1, wherein the compound of formula I is a compound of formula Ia: ##STR00027## or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the influenza infection is a type A influenza infection. 4. The method of claim 1, wherein the influenza infection is a seasonal influenza infection. 5. The method of claim 1, wherein the effective anti-viral amount is up to about 800 mg per day. 6. The method of claim 1, wherein the effective anti-viral amount is up to about 600 mg per day. 7. The method of claim 1, wherein the effective anti-viral amount is up to about 300 mg per day. 8. The method of claim 1, wherein the effective anti-viral amount is up to about 150 mg per day. 9. The method of claim 1, wherein the plasma concentration of the compound is higher than the IC.sub.50 of the virus causing the viral infection 12 hours following administration of the compound. 10. The method of claim 1, further comprising orally administering a neuraminidase inhibitor to the human. 11. The method of claim 10, wherein the neuraminidase inhibitor that is administered orally is oseltamivir carboxylate. 12. The method of claim 10, wherein the neuraminidase inhibitor that is administered orally is a compound of formula I, II, III, or IV: ##STR00028## or a pharmaceutically acceptable salt thereof. 13. The method of claim 10, wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, IIa, IIIa, or IVa: ##STR00029## or a pharmaceutically acceptable salt thereof. 14. The method of claim 13, wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, or a pharmaceutically acceptable salt thereof. 15. The method of claim 10, wherein the neuraminidase inhibitor that is administered orally is administered for up to 20 days. 16. The method of claim 10, wherein the neuraminidase inhibitor that is administered orally is administered for up to 5 days or up to 10 days. 17. The method of claim 1, wherein the effective anti-viral amount is up to about 1000 mg per day. 18. The method of claim 1, wherein the effective anti-viral amount is about 200 mg per day.